In other recent news, Rocket Pharmaceuticals has faced multiple analyst downgrades following significant developments in its clinical trials. The company reported a patient death in its RP-A501 trial for Danon disease, leading to a clinical hold by the FDA. This incident has prompted Evercore ISI to downgrade Rocket Pharmaceuticals from Outperform to In Line, slashing the price target from $18.00 to $5.00. Similarly, JPMorgan (NYSE: JPM ) downgraded the stock from Overweight to Neutral, reducing the price target from $44.00 to $7.00, due to concerns about regulatory hurdles following the clinical hold. Goldman Sachs (NYSE: GS ) also downgraded the company from Buy to Sell, with a new price target of $2.00, citing uncertainty about the commercial viability of RP-A501. Scotiabank (TSX: BNS ) adjusted its price target from $51.00 to $19.00 but maintained a Sector Outperform rating, acknowledging the potential for addressing safety concerns.